Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Heinrich-Heine-Universität Düsseldorf maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The portfolio's current activity is limited to 1 distinct examiner and 1 distinct art unit. This concentration reflects a specific research focus within the university's intellectual property holdings, likely targeting a specialized biological or pharmaceutical innovation. The singular nature of the pending workload suggests that the university is currently prioritizing a specific patent family over a broader filing strategy. This approach allows for a highly targeted prosecution path within the life sciences sector.
CASH, KAILEY ELIZABETH acts as the busiest examiner for the university, managing 1 busiest examiner pending action. This single action constitutes the total pending workload for the entity. Future filings may determine if the university expands its presence beyond this 1 art unit and examiner. Currently, the prosecution path is defined by the interactions between this 1 examiner and the university's legal representatives. Success in this 1 art unit will be the sole indicator of the university's immediate patenting success in the Biotechnology & Pharmaceuticals field. Practitioners should tailor their arguments to the specific tendencies of this examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CASH, KAILEY ELIZABETH | 1 | 28.6% | +64.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17617218 | INHIBITATION OF ACID LIPASE FOR CANCER THERAPY | CASH, KAILEY ELIZABETH | 86d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17617218 | INHIBITATION OF ACID LIPASE FOR CANCER THERAPY | CASH, KAILEY ELIZABETH | 86d |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17617218 | INHIBITATION OF ACID LIPASE FOR CANCER THERAPY | CASH, KAILEY ELIZABETH | 1683 | §103§112 | Non-Final OA | 86d | Pending | Dec 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial